Sign in Sign up for free

Last updated: 4 July 2020 at 1:03pm EST

Jay P. Madan Net Worth



Jay Madan NMTR stock SEC Form 4 insiders trading

Jay has made over 2 trades of the 9 Meters Biopharma stock since 2019, according to the Form 4 filled with the SEC. Most recently Jay bought 5,000 units of NMTR stock worth $6,600 on 30 May 2019.

The largest trade Jay's ever made was buying 5,000 units of 9 Meters Biopharma stock on 30 May 2019 worth over $6,600. On average, Jay trades about 2,500 units every 0 days since 2019. As of 30 May 2019 Jay still owns at least 84,131 units of 9 Meters Biopharma stock.

You can see the complete history of Jay Madan stock trades at the bottom of the page.



What's Jay Madan's mailing address?

Jay's mailing address filed with the SEC is C/O INNOVATE BIOPHARMACEUTICALS, INC.,, 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH, NC, 27615.

Insiders trading at 9 Meters Biopharma

Over the last 5 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo, and John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.



What does 9 Meters Biopharma do?

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.



What does 9 Meters Biopharma's logo look like?

9 Meters Biopharma, Inc. logo

9 Meters Biopharma executives and stock owners

9 Meters Biopharma executives and other stock owners filed with the SEC include: